By Dengyuemed International Business Department For decades, global oncology treatments have relied primarily on traditional modalities such as small-molecule inhibitors, antibody therapies, and cell therapies. However, challenges such as drug resistance, undruggable targets, and ...Learn More

By: DengYue International Business DivisionTen years ago, China was known primarily as a supplier of APIs and low-cost generic medicines to the world. Today, if someone tells you that China is developing, manufacturing, and exporting world-class oncology drugs, biologics, ...Learn More

By DengYueMed International Business DivisionToday, DengYueMed shares key commercial insights into China’s EGFR small-molecule targeted therapy market with international buyers and distribution partners. Drawing on the latest publicly available data, we analyzed the sales trends ...Learn More

As November 2025 arrives, the global pharmaceutical industry stands at a pivotal moment.In October alone, China saw six innovative drugs approved for market launch, including the world’s first EGFR-targeting Antibody–Drug Conjugate (ADC), Becotatugvedotin for Injection.This ...Learn More

Amerigo Scientific, a leading global provider of specialized reagents and consumables for the life science industry, announced the expansion of its product portfolio to include a comprehensive suite of high-purity extracellular vesicle (EV) research products. These new offerings ...Learn More